

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Shanghai HeartCare Medical Technology  
Corporation Limited**

**上海心璋醫療科技股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 6609)**

**ANNOUNCEMENT PURSUANT  
TO RULES 13.51B(2) AND 13.51(2)(n)(iv) OF THE LISTING RULES**

This announcement is made by Shanghai HeartCare Medical Technology Corporation Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rules 13.51B(2) and 13.51(2)(n)(iv) of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) in relation to Mr. Guo Shaomu (“**Mr. Guo**”), an independent non-executive director of the Company, in relation to his capacity as an independent non-executive director of Fantasia Holdings Group Co., Limited (a company listed on the Stock Exchange, stock code: 1777) (“**Fantasia**”).

Reference is made to the regulatory announcement (the “**Regulatory Announcement**”) published by the Stock Exchange on February 28, 2022 in relation to the disciplinary action against Fantasia, Colour Life Services Group Co., Limited (a company listed on the Stock Exchange, stock code: 1778) and certain directors or former directors of the two companies. According to the Regulatory Announcement, the Stock Exchange found that, among others, Fantasia was in breach of Code Provision C.2.1 of the Corporate Governance Code in Appendix 14 of the Listing Rules, the details of which are set forth in the Regulatory Announcement.

The Regulatory Announcement has also made clear that the disciplinary action stated therein does not apply to Mr. Guo. To the best of the knowledge and belief of the board of directors of the Company, the Regulatory Announcement (including the disciplinary action) is in any way unrelated to the Group nor Mr. Guo. Furthermore, there is no evidence, and the Company has no reason, to cast doubt upon Mr. Guo’s integrity and suitability as an independent non-executive director of the Company.

Save as disclosed above, there is no other information in relation to Mr. Guo that shall be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules, nor is there any other matter in relation thereto that shall be brought to the attention of the shareholders of the Company and the Stock Exchange.

By order of the Board  
**Shanghai HeartCare Medical Technology Corporation Limited**  
**Wang Guohui**  
*Chairman of the Board*

Shanghai, March 8, 2022

*As at the date of this announcement, the executive Directors are Mr. Wang Guohui and Ms. Zhang Kun; the non-executive Directors are Mr. Ding Kui, Mr. Chen Gang and Mr. Ouyang Xiangyu; and the independent non-executive Directors are Mr. Guo Shaomu, Mr. Feng Xiangqian and Mr. Gong Ping.*